ONCODESIGN PRECISION MEDICIN (ALOPM.PA) Fundamental Analysis & Valuation

EPA:ALOPM • FR001400CM63

Current stock price

0.483 EUR
-0.02 (-3.01%)
Last:

This ALOPM.PA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. ALOPM.PA Profitability Analysis

1.1 Basic Checks

  • In the past year ALOPM has reported negative net income.
  • In the past 5 years ALOPM always reported negative net income.
  • In the past 5 years ALOPM always reported negative operating cash flow.
ALOPM.PA Yearly Net Income VS EBIT VS OCF VS FCFALOPM.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -2M -4M -6M -8M

1.2 Ratios

  • ALOPM has a Return On Assets of -2.18%. This is in the better half of the industry: ALOPM outperforms 66.25% of its industry peers.
Industry RankSector Rank
ROA -2.18%
ROE N/A
ROIC N/A
ROA(3y)-38.13%
ROA(5y)-30.14%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALOPM.PA Yearly ROA, ROE, ROICALOPM.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 500 -500 1K 1.5K

1.3 Margins

  • Looking at the Gross Margin, with a value of 100.25%, ALOPM belongs to the top of the industry, outperforming 98.75% of the companies in the same industry.
  • ALOPM's Gross Margin has been stable in the last couple of years.
  • The Profit Margin and Operating Margin are not available for ALOPM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 100.25%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.78%
GM growth 5YN/A
ALOPM.PA Yearly Profit, Operating, Gross MarginsALOPM.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. ALOPM.PA Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, ALOPM has more shares outstanding
  • ALOPM has a worse debt/assets ratio than last year.
ALOPM.PA Yearly Shares OutstandingALOPM.PA Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 5M 10M 15M
ALOPM.PA Yearly Total Debt VS Total AssetsALOPM.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

  • ALOPM has an Altman-Z score of -1.45. This is a bad value and indicates that ALOPM is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -1.45, ALOPM is doing worse than 68.75% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -1.45
ROIC/WACCN/A
WACCN/A
ALOPM.PA Yearly LT Debt VS Equity VS FCFALOPM.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 2M 4M 6M 8M 10M

2.3 Liquidity

  • A Current Ratio of 0.87 indicates that ALOPM may have some problems paying its short term obligations.
  • ALOPM has a Current ratio of 0.87. This is in the lower half of the industry: ALOPM underperforms 71.25% of its industry peers.
  • A Quick Ratio of 0.87 indicates that ALOPM may have some problems paying its short term obligations.
  • ALOPM's Quick ratio of 0.87 is on the low side compared to the rest of the industry. ALOPM is outperformed by 70.00% of its industry peers.
Industry RankSector Rank
Current Ratio 0.87
Quick Ratio 0.87
ALOPM.PA Yearly Current Assets VS Current LiabilitesALOPM.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. ALOPM.PA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 18.37% over the past year.
  • The Revenue for ALOPM has decreased by -80.37% in the past year. This is quite bad
  • ALOPM shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -62.01% yearly.
EPS 1Y (TTM)18.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)-80.37%
Revenue growth 3Y-62.01%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • ALOPM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 49.26% yearly.
  • The Revenue is expected to grow by 78.65% on average over the next years. This is a very strong growth
EPS Next Y95%
EPS Next 2Y247.49%
EPS Next 3Y49.26%
EPS Next 5YN/A
Revenue Next Year151.06%
Revenue Next 2Y365.39%
Revenue Next 3Y78.65%
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ALOPM.PA Yearly Revenue VS EstimatesALOPM.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M 80M 100M
ALOPM.PA Yearly EPS VS EstimatesALOPM.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 0 1 2 3 4

More info and screens

Find the best growth stocksShow best growing peers

1

4. ALOPM.PA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ALOPM. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALOPM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALOPM.PA Price Earnings VS Forward Price EarningsALOPM.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALOPM.PA Per share dataALOPM.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4

4.3 Compensation for Growth

  • ALOPM's earnings are expected to grow with 49.26% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y247.49%
EPS Next 3Y49.26%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ALOPM.PA Dividend Analysis

5.1 Amount

  • ALOPM does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ALOPM.PA Fundamentals: All Metrics, Ratios and Statistics

ONCODESIGN PRECISION MEDICIN

EPA:ALOPM (3/30/2026, 7:00:00 PM)

0.483

-0.02 (-3.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A
Earnings (Next)04-03
Inst Owners0.2%
Inst Owner ChangeN/A
Ins Owners8.56%
Ins Owner ChangeN/A
Market Cap8.93M
Revenue(TTM)7.98M
Net Income(TTM)-240.00K
Analysts84.44
Price Target2.04 (322.36%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.12
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.3
EYN/A
EPS(NY)-0.02
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.43
BVpS0
TBVpS-0.06
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -2.18%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 100.25%
FCFM N/A
ROA(3y)-38.13%
ROA(5y)-30.14%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.78%
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.73
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.87
Quick Ratio 0.87
Altman-Z -1.45
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y95%
EPS Next 2Y247.49%
EPS Next 3Y49.26%
EPS Next 5YN/A
Revenue 1Y (TTM)-80.37%
Revenue growth 3Y-62.01%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year151.06%
Revenue Next 2Y365.39%
Revenue Next 3Y78.65%
Revenue Next 5YN/A
EBIT growth 1Y21.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year106.11%
EBIT Next 3Y52.59%
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

ONCODESIGN PRECISION MEDICIN / ALOPM.PA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of ONCODESIGN PRECISION MEDICIN (ALOPM.PA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to ALOPM.PA.


What is the valuation status of ONCODESIGN PRECISION MEDICIN (ALOPM.PA) stock?

ChartMill assigns a valuation rating of 1 / 10 to ONCODESIGN PRECISION MEDICIN (ALOPM.PA). This can be considered as Overvalued.


How profitable is ONCODESIGN PRECISION MEDICIN (ALOPM.PA) stock?

ONCODESIGN PRECISION MEDICIN (ALOPM.PA) has a profitability rating of 2 / 10.


Can you provide the financial health for ALOPM stock?

The financial health rating of ONCODESIGN PRECISION MEDICIN (ALOPM.PA) is 0 / 10.